Steve Soper's Biography

Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas

Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.

As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.

Circulating Cells and Extracellular Vesicles as a Source of mRNA for the In Vitro Diagnostics of Acute Ischemic and Hemorrhagic Strokes

Thursday, 27 July 2023 at 09:00

Add to Calendar ▼2023-07-27 09:00:002023-07-27 10:00:00Europe/LondonCirculating Cells and Extracellular Vesicles as a Source of mRNA for the In Vitro Diagnostics of Acute Ischemic and Hemorrhagic StrokesExtracellular Vesicles 2023: Drug Delivery, Biologics and Therapeutics in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Stroke is the third leading killer in the US and the main cause of over 795,000 cases of adult disability each year. The two major types of stroke, ischemic and hemorrhagic, cannot be clinically differentiated; 30% of patients presenting stroke-like symptoms do not have stroke and <5% of stroke patients are treated with available therapeutics (recombinant tissue plasminogen activator for acute ischemic stroke). Computed tomography is commonly used for diagnosis, which provides a clinical sensitivity of only 25%, and in most cases, does not provide clinical information to meet the necessary time requirements for proper therapeutic administration (<4.5 h). Unfortunately, there are no FDA-approved in vitro diagnostic tests for stroke that could address the aforementioned issues. In this presentation, we will provide data on the use of liquid biopsy markers, in particular circulating extracellular vesicles (EVs – CD8 and CD15 expressing EVs) as a source of mRNA to diagnose ischemic and hemorrhagic stroke. Isolation technologies used for the timely enrichment of the appropriate liquid biopsy markers along with rapid reporting molecular assays of mRNA expression will be presented that provide clinical information to assess the status of the patient in terms of a stroke mimic or ischemic/hemorrhagic stroke in a timely manner. Appropriate mRNA gene panels will be presented that provide high clinical sensitivity and specificity for the in vitro diagnostic assay.

Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonExtracellular Vesicles 2023: Drug Delivery, Biologics and TherapeuticsExtracellular Vesicles 2023: Drug Delivery, Biologics and Therapeutics in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors